We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Immunovant, Inc. (IMVT - Free Report) . Shares have added about 7.8% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Immunovant due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Immunovant’s Q1 Loss Narrower Than Expected, Pipeline in Focus
Immunovantreported first-quarter fiscal 2026 adjusted net loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, the company reported a loss of 60 cents per share.
Currently, Immunovant does not have any approved products in its portfolio. As a result, it has yet to generate revenues.
IMVT’s Q1 Results in Detail
Research and development expenses totaled $101.2 million, up 34% from the year-ago quarter’s figure. The uptick can be attributed to activities related to the clinical studies of IMVT-1402, including contract manufacturing costs for drug substance and increased personnel-related expenses. The increase was partially offset by lower overall costs related to Immunovant’s batoclimab pivotal clinical studies and nonclinical studies.
General and administrative expenses amounted to $26 million, up 38% year over year. The rise was primarily due to an increase in personnel-related expenses.
As of June 30, 2025, Immunovant had a cash balance of $598.9 million compared with $714 million as of March 31, 2025. IMVT expects its cash runway to fund clinical activities through 2027.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
Currently, Immunovant has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending downward for the stock, and the magnitude of these revisions looks promising. Notably, Immunovant has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Immunovant belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Alkermes (ALKS - Free Report) , has gained 1.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2025.
Alkermes reported revenues of $390.66 million in the last reported quarter, representing a year-over-year change of -2.1%. EPS of $0.52 for the same period compares with $0.72 a year ago.
Alkermes is expected to post earnings of $0.41 per share for the current quarter, representing a year-over-year change of -43.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -6.3%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Alkermes. Also, the stock has a VGM Score of A.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Immunovant, Inc. (IMVT - Free Report) . Shares have added about 7.8% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Immunovant due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Immunovant’s Q1 Loss Narrower Than Expected, Pipeline in Focus
Immunovantreported first-quarter fiscal 2026 adjusted net loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, the company reported a loss of 60 cents per share.
Currently, Immunovant does not have any approved products in its portfolio. As a result, it has yet to generate revenues.
IMVT’s Q1 Results in Detail
Research and development expenses totaled $101.2 million, up 34% from the year-ago quarter’s figure. The uptick can be attributed to activities related to the clinical studies of IMVT-1402, including contract manufacturing costs for drug substance and increased personnel-related expenses. The increase was partially offset by lower overall costs related to Immunovant’s batoclimab pivotal clinical studies and nonclinical studies.
General and administrative expenses amounted to $26 million, up 38% year over year. The rise was primarily due to an increase in personnel-related expenses.
As of June 30, 2025, Immunovant had a cash balance of $598.9 million compared with $714 million as of March 31, 2025. IMVT expects its cash runway to fund clinical activities through 2027.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
Currently, Immunovant has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending downward for the stock, and the magnitude of these revisions looks promising. Notably, Immunovant has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Immunovant belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Alkermes (ALKS - Free Report) , has gained 1.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2025.
Alkermes reported revenues of $390.66 million in the last reported quarter, representing a year-over-year change of -2.1%. EPS of $0.52 for the same period compares with $0.72 a year ago.
Alkermes is expected to post earnings of $0.41 per share for the current quarter, representing a year-over-year change of -43.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -6.3%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Alkermes. Also, the stock has a VGM Score of A.